Yael Baratz is a Senior Partner and Chair of the Corporate & Licensing Group at Pearl Cohen's Tel Aviv office. With expertise in the full range of cross border corporate transactions, particularly in the high-tech and biotech industries, Yael advises global leading entities and influential individuals on a broad range of corporate and commercial matters, including cross border mergers and acquisitions, internal and external investment rounds, technology licensing and other collaborations and non-dilutive financing (including grants from the Israel Innovation Authority of the Israeli Ministry of Economy, previously known as the Office of the Chief Scientist or OCS). Yael is considered as one of the leading lawyers in Israel on the subject of university licensing, and counsels many of Israel’s leading research institutions. Yael also has vast experience in international joint ventures and in representing foreign contractors in teaming with local companies in bidding and carrying out large public infrastructure projects. Yael’s clients include Israeli and foreign publicly traded tech and bio companies, university and hospital technology transfer offices, large infrastructure contractors and start-ups.
Yael is considered a prime resource for legal advice and an expert on cross border transactions. She has been named by global directories, including Who’s Who Legal and LMG Life Sciences as a leading attorney in the Life Sciences sector.
Furthermore, Yael served for several years as a judge on the National Disciplinary Tribunal of the Israel Bar Association, which hears appeals, and currently serves as Co-Chair of the Israel Bar Association's Science and Technology Committee.
New to the IAM Patent 1000 litigation and transactions firm tables this year, Pearl Cohen has a plethora of technical talent with considerable bandwidth (including more than 40 PhDs) and a truly global footprint. “Pearl Cohen is a tech-oriented firm… its approach balances highly impressive practitioners with a creative, holistic, thorough and inspiration-driven outlook; it also has a keen sense for collaborating with world-class scientists and advisers to complete the full scope of its legal work.” On the litigation side, Yossi Markovich enjoys an outstanding market reputation, with one peer describing him as “a great friend, rival and a true gentleman”. Serving this year as chair of the Israel Bar Association IP committee and the American-Israel Chamber of Commerce, Markovich has a talent for IP dispute resolution and complex litigation. He has been instrumental in filing oppositions this year on behalf of German arms giant Diehl, Israel’s largest private pharmaceutical company Dexcel and in an intricate patent ownership dispute on behalf of the Hebrew University’s technology transfer department. Masterminding Pearl Cohen’s strategic operation is its eponymous managing partner Zeev Pearl, whose wide range of practices – licensing, litigation support and portfolio development – encapsulate the breadth his firm has to offer prospective clients. “His understanding of patent law is unprecedented. We rely on his strategic leadership, extraordinary expertise in the IP world and his impeccable team execution to represent us.” Also integral to Pearl Cohen’s gold-plated transactional reputation is Yael Baratz, whose all-around expertise in licensing for technology transfers has helped OPKO Health Inc, among others. Pearl Cohen is a firm on the rise, with big ambitions for the Israeli patent market.